Association Between Statins and the Risk of Kidney Cancer Incidence and Mortality Using the Korean National Health Insurance Claims Database

Overview

Journal Cancer Control

Specialty Oncology

Date 2022 Aug 18

PMID 35980770

Authors

Dong-Sook Kim

Hyun Jung Kim

Hyeong Sik Ahn

Affiliations

Soon will be listed here.

Abstract

Background: Conflicting results have been reported regarding the potential preventive effects of statins on the risk of cancer. This study investigated the associations of statin use with the incidence and mortality of kidney cancer in South Korea.

Methods: In this retrospective population-based cohort study using the National Health Insurance claims database, we compared patients aged 45-70 years who had used statins for at least 6 months to non-statin users matched by age and sex from 2005 to June 2013. The main outcomes were kidney cancer incidence and mortality according to statin use. Cox proportional hazard regression was used to calculate the adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs).

Results: In the cohort of 1 008 101 people, the aHRs for the association between statin use and the outcomes were .84 (95% CI: 0.71-.99) for kidney cancer incidence and .65 (95% CI: 0.41-.98) for kidney cancer mortality. In the matched cohort of 337 578, the risk per 1000 people of cancer incidence and mortality was 1.63, 1.07, and .24, .17 in statin users and non-users, respectively. In matched cohort, the risk of kidney cancer incidence and mortality decreased, but it is not statistically significant. Also, there was no linear relationship with increased doses.

Conclusion: Statin use might be associated with a decreased risk of kidney cancer incidence and mortality, but it showed no statistical significance. This study was a large-scale analysis, however, further studies that are larger and multinational in scope are needed to confirm the beneficial effects of statins on survival.

Citing Articles

Longitudinal cohort study highlights cancer-preventive benefits of lipid-lowering drugs.

Yuan Z, Ding C, Duan J, Lian R, Shi Y, Han J iScience. 2024; 27(9):110680.

PMID: 39252980 PMC: 11381893. DOI: 10.1016/j.isci.2024.110680.

Adjusting for Confounders in Outcome Studies Using the Korea National Health Insurance Claim Database: A Review of Methods and Applications.

Han S, Kim K J Prev Med Public Health. 2023; 57(1):1-7.

PMID: 38013409 PMC: 10861329. DOI: 10.3961/jpmph.23.250.

References

Pottegard A, Clark P, Friis S, Hallas J, Lund L . Long-term Use of Statins and Risk of Renal Cell Carcinoma: A Population-based Case-Control Study. Eur Urol. 2015; 69(5):877-82. DOI: 10.1016/j.eururo.2015.10.020. View

Jeong G, Lee K, Kim J, Eisenhut M, Kronbichler A, van der Vliet H . Effect of Statin on Cancer Incidence: An Umbrella Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(6). PMC: 6617015. DOI: 10.3390/jcm8060819. View

Ryzhov A, Bray F, Ferlay J, Fedorenko Z, Goulak L, Gorokh Y . Recent cancer incidence trends in Ukraine and short-term predictions to 2022. Cancer Epidemiol. 2019; 65:101663. DOI: 10.1016/j.canep.2019.101663. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

Khurana V, Caldito G, Ankem M . Statins might reduce risk of renal cell carcinoma in humans: case-control study of 500,000 veterans. Urology. 2008; 71(1):118-22. DOI: 10.1016/j.urology.2007.08.039. View

Scelo G, Larose T . Epidemiology and Risk Factors for Kidney Cancer. J Clin Oncol. 2018; :JCO2018791905. PMC: 6299342. DOI: 10.1200/JCO.2018.79.1905. View

Kocher N, Rjepaj C, Robyak H, Lehman E, Raman J . Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer. World J Urol. 2016; 35(1):67-72. DOI: 10.1007/s00345-016-1850-2. View

Chow W, Gridley G, Fraumeni Jr J, Jarvholm B . Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000; 343(18):1305-11. DOI: 10.1056/NEJM200011023431804. View

Shaw S, Fildes J, Yonan N, Williams S . Pleiotropic effects and cholesterol-lowering therapy. Cardiology. 2008; 112(1):4-12. DOI: 10.1159/000137692. View

10.

Choi M, Jee S, Sull J, Nam C . The effect of hypertension on the risk for kidney cancer in Korean men. Kidney Int. 2005; 67(2):647-52. DOI: 10.1111/j.1523-1755.2005.67137.x. View

11.

Chiu H, Kuo C, Kuo H, Lee I, Lee C, Yang C . Statin use and the risk of kidney cancer: a population-based case-control study. Expert Opin Drug Saf. 2012; 11(4):543-9. DOI: 10.1517/14740338.2012.678831. View

12.

Hong S, Won Y, Lee J, Jung K, Kong H, Im J . Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018. Cancer Res Treat. 2021; 53(2):301-315. PMC: 8053867. DOI: 10.4143/crt.2021.291. View

13.

Zhang X, Liu M, Qian J, Zheng J, Zhang X, Guo C . Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. Br J Clin Pharmacol. 2013; 77(3):458-65. PMC: 3952720. DOI: 10.1111/bcp.12210. View

14.

Brennan P, van der Hel O, Moore L, Zaridze D, Matveev V, Holcatova I . Tobacco smoking, body mass index, hypertension, and kidney cancer risk in central and eastern Europe. Br J Cancer. 2008; 99(11):1912-5. PMC: 2600689. DOI: 10.1038/sj.bjc.6604761. View

15.

Wu P, Xiang T, Wang J, Lv R, Zhuang Y, Wu G . Statin use and the overall survival of renal cell carcinoma: A meta-analysis. Clin Invest Med. 2020; 43(4):E17-23. DOI: 10.25011/cim.v43i4.34908. View

16.

Seo H, Oh I, Yoon S . A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev. 2013; 13(12):6163-8. DOI: 10.7314/apjcp.2012.13.12.6163. View

17.

Nayan M, Punjani N, Juurlink D, Finelli A, Austin P, Kulkarni G . Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. Cancer Treat Rev. 2016; 52:105-116. DOI: 10.1016/j.ctrv.2016.11.009. View

18.

Hidayat K, Du X, Zou S, Shi B . Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017; 35(7):1333-1344. DOI: 10.1097/HJH.0000000000001286. View

19.

Bocan T . Pleiotropic effects of HMG-CoA reductase inhibitors. Curr Opin Investig Drugs. 2002; 3(9):1312-7. View

20.

Kaffenberger S, Lin-Tsai O, Stratton K, Morgan T, Barocas D, Chang S . Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol. 2014; 33(1):21.e11-21.e17. PMC: 4274038. DOI: 10.1016/j.urolonc.2014.10.007. View